^
    Back
    Association details:
    Biomarker:BRAF V600
    Cancer:Melanoma
    Drug:Mektovi (binimetinib) (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors

    Excerpt:
    ...- Patients with advanced solid tumors (CRC, melanoma) with documented somatic KRAS or BRAFV600 mutations in tumor tissue....
    Trial ID:
    NCT01562899
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Lancet Oncol
    Title:

    MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

    Excerpt:
    Six (20%) of 30 patients with NRAS-mutated melanoma had a partial response (three confirmed) as did eight (20%) of 41 patients with BRAF-mutated melanoma (two confirmed). The most frequent adverse events were acneiform dermatitis (18 [60%] patients with NRAS -mutated melanoma.
    DOI:
    10.1016/S1470-2045(13)70024-X
    Trial ID:
    NCT01320085